Research Article

The Association between Yang-Deficient Constitution and Clinical Outcome of Highly Active Antiretroviral Therapy on People Living with HIV

Table 5

(a) Univariate analysis of Yang deficiency in HIV patients. (b) Logistic regression analysis of risk factors for mortality.
(a)

VariableCategoryNumber/IQRCorrelation coefficientYang deficiency median score value*

GenderMale96N/A22.32<0.05
Female4632.14
Hepatotoxicity Yes4 9N/A32.14<0.1
No9325.00
Nephrotoxicity Yes11N/A37.50<0.1
No13125.00
HIV disease stagingA57N/A23.21<0.05
B1634.82
C6925.00
Mortality Yes137N/A39.29<0.05
No525.00
AgeN/A29–41−0.028ND0.74
CD4Annual change77–217−0.028ND0.75
Nadir value 19–194−0.053ND0.53
CD8Annual change−138–510−0.028ND0.74
Nadir value 334–737−0.13ND0.12
Total number of adverse eventsN/A1–50.16ND<0.1

Wilcoxon rank sum test with continuity correction, Spearman’s rank correlation, and Kruskal-Wallis rank sum test were performed where appropriate.
(b)

VariableAliveDead OROR 95% CI

Previous pneumoniaNo991<0.0510.421.48, 207.38
Yes384
Intestinal infectionsNo1313<0.0514.551.69, 106.00
Yes62
IRISNo1303<0.0512.381.46, 87.72
Yes72
Total number of newly acquired infections after HAARTN/AN/AN/A<0.051.631.20, 2.41
Hepatotoxicity No921<0.058.181.17, 162.48
Yes454
NephrotoxicityNo1292<0.0524.193.55, 205.36
Yes83
Total number of adverse eventsN/AN/AN/A<0.057.851.35, 149.63